 Patients with newly diagnosed CML have excellent outcomes with tyrosine kinase inhibitors TKI. However, a few patients will be cured with TKIs alone, and thus need continued life-long treatment. Some patients achieve complete molecular remission CMR, and this rate is higher with second generation TKIs compared with imatinib. Some experience with drug discontinuation in CMR has been derived from a few small studies, most notably the French STIM study. Approximately 40 of patients with a minimum of two years in MR4.5 4.5 log reduction in molecular response can stop imatinib without relapse, indicating possible cure. To increase the non-relapse rate is of major importance. To achieve a permanent cure without stem cell transplantation is presently the most relevant goal of clinical studies in CML. 